Thirdly, there is a strong financial case for choosing MPox as the indication. This business case has become even stronger with the failure of tecovirimat (Tpoxx) in clinical trial against MPox.

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate ...

The advisory committee makes recommendations to the Centers for Disease Control and Prevention on the nation's vaccine schedule. Any changes could affect vaccinations for millions of children.

The preservative thimerosal has been removed from all but a few vaccines, and studies have confirmed no link to neurodevelopmental issues including autism. So public health experts were puzzled ...